Brief: Talaris Therapeutics Provides FREEDOM-1 Phase 3 Clinical Update

Tourmaline Bio

30/06/2022 12:22

June 30 (Reuters) - Talaris Therapeutics Inc  TALS.O :
    * TALARIS THERAPEUTICS PROVIDES FREEDOM-1 PHASE 3 CLINICAL
UPDATE
    * TALARIS THERAPEUTICS - ALL 3 FREEDOM-1 PATIENTS TREATED
WITH
FCR001 WHO ARE MORE THAN 12 MONTHS POST-TRANSPLANT SUCCESSFULLY
WEANED OFF CHRONIC ANTI-REJECTION DRUGS
    * TALARIS THERAPEUTICS - ALL FREEDOM-1 PATIENTS WHO RECEIVED
FCR001 AT LEAST 3 MONTHS PRIOR TO DATA CUTOFF DATE ACHIEVED,
MAINTAINED >50% T-CELL CHIMERISM

Source text for Eikon:  ID:nGNX3zmH5b 
Further company coverage:  TALS.O 

 ((Reuters.Briefs@thomsonreuters.com;))